Dosage · As studied, not as advised
PT-141 Dosage as Studied in Clinical Research
The label and trial doses, reported as findings — 1.75 mg subcutaneous, as-needed, capped at one per 24 hours and eight per month. A record of what was administered, not a protocol to follow.
Before the details
This page reports the PT-141 dosage exactly as the trials and the FDA label state it — as documented findings, not a regimen for any reader to follow. The approved dose is 1.75 mg injected just under the skin (subcutaneous), used as needed, no more than once in 24 hours and no more than eight times a month [13]. Earlier studies compared a few doses to settle on that one. None of this is medical advice, and material sold as a "research chemical" is not the approved drug. With that framing fixed, here is the record.
PT-141 Dosage as Studied in Clinical Research
The approved regimen, per the US prescribing information, is 1.75 mg subcutaneous, as needed, given at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and no more than 8 doses per month [13]. That dose and cap are for the single approved indication — acquired, generalized HSDD in premenopausal women — and reflect both the efficacy data and the tolerability findings, including nausea and the transient blood-pressure effect [4][13].
The dose was settled by dose-finding research. A randomized, placebo-controlled study evaluated subcutaneous bremelanotide at 0.75, 1.25, and 1.75 mg in premenopausal women with female sexual dysfunction, and 1.75 mg was advanced to the Phase 3 program and the label [9]. A Phase 2b responder analysis examined the proportion of women reaching clinically meaningful improvement across doses, supporting the benefit–risk basis for the selected dose [10]. These are research and label doses; this digest summarizes them and recommends no dose for any individual. This is the PT-141 dosage as studied in clinical research, nothing more.
Routes Studied and How the Drug Is Formulated
Three routes appear in the development record: subcutaneous (the approved route), intranasal (used in early development, then discontinued due to pharmacokinetic variability), and intravenous (early pharmacology) [6][7][13]. The approved finished product is a prefilled subcutaneous autoinjector, not a reconstituted powder, and the cyclic lactam structure is more stable than linear melanocortin peptides [13]. Material sold as "PT-141 research chemical" is a separate thing entirely — for laboratory use only, outside the approval framework, with no verified identity or concentration [13]. Early high-frequency Phase 1 metabolic research in women used subcutaneous dosing up to 2.5 mg up to three times daily for 15 days, but that was a research protocol probing appetite effects, not an approved or recommended regimen [13].
What Is the PT-141 Dosage?
The US prescribing information specifies 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and no more than 8 doses per month [13]. This is a documented regimen, not a recommendation to follow.
Doses Studied in the Trials
Phase 2 subcutaneous dose-finding in women evaluated 0.75, 1.25, and 1.75 mg, and 1.75 mg was advanced to the Phase 3 program and the label [9]. These are research and label doses; this digest summarizes findings and recommends no dose for any individual.
Injection Amount in the Approved Regimen
The approved subcutaneous regimen is a single 1.75 mg dose as needed, capped at one per 24 hours [13]. Early development also studied intranasal and intravenous routes before the subcutaneous formulation was selected [6][7].
PT-141 Dosage for Women in the Approved Indication
For the approved indication (HSDD in premenopausal women), the label dose is 1.75 mg subcutaneously, as needed, no more than once per 24 hours and no more than 8 times per month [13]. The dose-finding trial that supported it compared 0.75, 1.25, and 1.75 mg [9].
Formulation and Handling in the Research Record
The approved finished product is a prefilled subcutaneous autoinjector, not a reconstituted powder; the cyclic lactam structure is more stable than linear melanocortin peptides [13]. Material sold as "PT-141 research chemical" is for laboratory use only and is not the approved drug product [13].
Route of Administration in the Trials
In the pivotal trials and the label, bremelanotide is given subcutaneously as a single as-needed dose at least 45 minutes before anticipated activity [13]. Intranasal delivery was used in early development but discontinued due to pharmacokinetic variability [6].
Dosing Frequency Limits on the Label
The label limits use to no more than one 1.75 mg dose per 24 hours and no more than 8 doses per month [13]. The frequency cap reflects tolerability findings, including nausea, and the transient blood-pressure effect seen with dosing [4][13].
The Approved Bremelanotide Dose
Per the US prescribing information, the approved bremelanotide dose is 1.75 mg subcutaneous, as needed, with a maximum of one dose per 24 hours and 8 doses per month, for acquired, generalized HSDD in premenopausal women [13].
Field reports (not clinical data)
What follows records commonly-described community impressions about timing and route. These are unverified user reports — not peer-reviewed, not tied to any study, and not advice. No figure here is a clinical measurement, and nothing here is a regimen to copy.
In discussion communities, people frequently describe dosing well before anticipated activity, echoing the label's 45-minute timing, and some describe starting with smaller amounts because of nausea — directionally consistent with the documented tolerability record but not a measured or recommended schedule [4][13]. The cited label and trial doses above are the evidence; these impressions are not, and the safest reading of this entire page is that it documents what was studied, not what anyone should do.